More than two years after federal regulators warned of this potential risk, Lipitor patients who allegedly developed diabetes because of this medication continue to contact our Firm on a regular basis.
New York, New York (PRWEB) November 19, 2014
Lipitor lawsuit (http://www.lipitorlawsuitcenter.com/ ) filings brought on behalf of individuals who allegedly developed new-onset Type 2 diabetes continue to mount in the federal multidistrict litigation now underway in U.S. District Court, District of South Carolina, Bernstein Liebhard LLP reports. According to an updated docket report issued by the U.S. Judicial Panel on Multidistrict Litigation on November 17th, at least 1,451 claims are now pending in the proceeding. Court records indicate that 96 new Lipitor lawsuits were filed in the litigation since October 15th, when 1,355 cases were reported. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)
“More than two years after federal regulators warned of this potential risk, Lipitor patients who allegedly developed diabetes because of this medication continue to contact our Firm on a regular basis. We are not surprised that the number of Lipitor lawsuits continues to increase steadily in the federal litigation,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free and confidential case reviews to individuals who may have been harmed by Lipitor.
Lipitor Diabetes Allegations
In February 2012, the U.S. Food & Drug Administration (FDA) warned of the potential for Lipitor and other statins to cause diabetes. At that time, the agency ordered the manufacturers of statin drugs to include information on their labels regarding a possible association between their use and Type 2 diabetes. The FDA acted after a study published in JAMA: Internal Medicine indicated that women using the medications may be at an increased risk of developing the disease.*
According to court documents, all of the Lipitor lawsuits pending in the federal litigation allege that the label modification instituted by Pfizer, Inc. in the wake FDA’s 2012 alert was inadequate, and still does not sufficiently warn Lipitor users that they may be at increased risk for Type 2 diabetes. Plaintiffs also claim that Pfizer was aware of this potential risk prior to the label update, but concealed this information from patient and doctors.
Type 2 diabetes patients who allegedly developed the disease due to their use of Lipitor may be entitled to compensation from Pfizer. To learn more http://www.lipitorlawsuitcenter.com/lipitor-diabetes/ about filing a Lipitor lawsuit, please visit Bernstein Liebhard LLP’s website, or call 800-511-5092 to obtain a free legal review.
*archinte.jamanetwork.com/article.aspx?articleid=1108676, JAMA Internal Medicine, January 2012
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com